Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jazz Pharma Plc (NQ: JAZZ )

156.40 -1.37 (-0.87%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 316,236
Open 157.26
Bid (Size) 155.24 (1)
Ask (Size) 157.40 (2)
Prev. Close 157.77
Today's Range 154.70 - 157.40
52wk Range 125.36 - 169.98
Shares Outstanding 62,311,104
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
CBD-Based Life-Changing Drug For Tuberous Sclerosis Patients, Epidiolex, Now Available Via England's NHS
The National Health Service England confirmed Tuesday that starting this week, doctors can prescribe Jazz Pharmaceuticals (NASDAQ: JAZZ) Epidiolex, a CBD-based medicine, to patients suffering from... 
Via Benzinga
3 Cannabis Stocks With Double-Digit Percentage Revenue Growth
Their shares may be down, but their sales are up. 
Via The Motley Fool

Performance

YTD
+0.03%
+0.03%
1 Month
+0.03%
+0.03%
3 Month
+7.86%
+7.86%
6 Month
+3.46%
+3.46%
1 Year
+11.13%
+11.13%

More News

Read More
The Ultimate Growth Stocks to Buy With $300 Right Now
Via The Motley Fool
2 Promising New Growth Stocks to Watch in 2023
Via The Motley Fool
Jazz Pharma, Zymeworks Highlight 84% Overall Survival At 18 Months From Zanidatamab In Esophageal Cancer
Via Benzinga
Will Investors Notice Exciting Sign On Jazz Pharmaceuticals's Chart?
Via Benzinga
2 Cannabis Stocks to Buy for the Long Haul
Via The Motley Fool
Jazz Pharma Opts In, Advances Zanidatamab Partnership With Zymeworks
Via Benzinga
6 Analysts Have This to Say About Jazz Pharmaceuticals
Via Benzinga
2 Stocks That Beat the Market in 2022 and That Analysts Think Can Go Higher
Via The Motley Fool
These Stocks Jumped 100% and 30% Last Year. Here's Why They're Still a Buy.
Via The Motley Fool
Jazz Pharmaceuticals Files Patent Infringement Against Generic Drugmakers In New Jersey's District Court
Via Benzinga
2 Growth Stocks to Buy Heading Into 2023
Via The Motley Fool
2 Top Biotech Stocks to Buy for the Long Haul
Via The Motley Fool
Better Buy: Moderna vs Axsome
Via The Motley Fool
What 6 Analyst Ratings Have To Say About Jazz Pharmaceuticals
Via Benzinga
Tesla, Amazon, Micron, Sintx, Zymeworks: Why These 5 Stocks Are Drawing Investors' Attention Today
Via Benzinga
After Jumping 100%, Is Axsome a Buy Before 2023?
Via The Motley Fool
Netflix To Rally Around 29%? Here Are 10 Other Price Target Changes For Friday
Via Benzinga
2 Unstoppable Growth Stocks to Buy in 2022 and Beyond
Via The Motley Fool
3 Fierce Stocks That Are Screaming Buys in December
Via The Motley Fool
Jazz Caregiver Survey: CBD-Based Epidiolex Improves Seizure & Non-Seizure Outcomes In Patients With Severe Epilepsy
Via Benzinga
Biotech Space Offers Reward In 2023 Despite Economic Risks
Via Talk Markets
Struggling Axsome Stock Could Bounce Back on Drug Trial Success
Via MarketBeat
Exposures Product Safety
Q3 Proves To Be Another Tough Quarter For Cannabis
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.